Protein engineering of diphtheria toxin. Development of receptor-specific cytotoxic agents for the treatment of human disease.
Murphy
J R
JR
University Hospital, Boston, Massachusetts.
Lakkis
F G
FG
vanderSpek
J C
JC
Anderson
P
P
Strom
T B
TB
D000595:Amino Acid Sequence; D004167:Diphtheria Toxin / Q000235:genetics* / Q000378:metabolism / Q000627:therapeutic use; D006801:Humans; D000922:Immunotoxins / Q000235:genetics* / Q000378:metabolism / Q000627:therapeutic use; D007376:Interleukin-2 / Q000235:genetics* / Q000378:metabolism / Q000627:therapeutic use; D008969:Molecular Sequence Data; D015202:Protein Engineering; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D013329:Structure-Activity Relationship
C054780:DAB(486)-interleukin 2; D004167:Diphtheria Toxin; D000922:Immunotoxins; D007376:Interleukin-2; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins